SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-033732
Filing Date
2021-06-22
Accepted
2021-06-22 07:15:33
Documents
13
Period of Report
2021-06-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ntla-8k_20210621.htm   iXBRL 8-K 46422
2 EX-99.1 ntla-ex991_6.htm EX-99.1 41067
  Complete submission text file 0001564590-21-033732.txt   230672

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20210621.xsd EX-101.SCH 5768
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20210621_lab.xml EX-101.LAB 19472
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20210621_pre.xml EX-101.PRE 11626
6 EXTRACTED XBRL INSTANCE DOCUMENT ntla-8k_20210621_htm.xml XML 3550
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 211033051
SIC: 2835 In Vitro & In Vivo Diagnostic Substances